Heba Ijaz

874 total citations
4 papers, 99 citations indexed

About

Heba Ijaz is a scholar working on Molecular Biology, Oncology and Neurology. According to data from OpenAlex, Heba Ijaz has authored 4 papers receiving a total of 99 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Molecular Biology, 3 papers in Oncology and 2 papers in Neurology. Recurrent topics in Heba Ijaz's work include Cancer therapeutics and mechanisms (2 papers), Neuroblastoma Research and Treatments (2 papers) and PARP inhibition in cancer therapy (2 papers). Heba Ijaz is often cited by papers focused on Cancer therapeutics and mechanisms (2 papers), Neuroblastoma Research and Treatments (2 papers) and PARP inhibition in cancer therapy (2 papers). Heba Ijaz collaborates with scholars based in United States and Switzerland. Heba Ijaz's co-authors include Yan Dai, Martin H. Steinberg, Brenda J. Weigel, Kristina A. Cole, Stephan D. Voss, John M. Maris, Charles G. Minard, Xiaowei Liu, Elizabeth Fox and Joel M. Reid and has published in prestigious journals such as Cancer, Cancer Research and Clinical Cancer Research.

In The Last Decade

Heba Ijaz

4 papers receiving 98 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Heba Ijaz United States	3	71	37	25	15	14	4	99
Sander Lambo Germany	4	70 1.0×	36 1.0×	17 0.7×	14 0.9×	31 2.2×	6	115
Susanne Gröbner Germany	4	66 0.9×	38 1.0×	20 0.8×	3 0.2×	9 0.6×	4	99
Ellen Fraint United States	5	44 0.6×	11 0.3×	19 0.8×	16 1.1×	18 1.3×	13	89
André Bortolini Silveira Brazil	5	69 1.0×	24 0.6×	28 1.1×	35 2.3×	6 0.4×	5	120
Haiying Kong China	3	34 0.5×	31 0.8×	26 1.0×	8 0.5×	11 0.8×	5	77
Eveline S. de Bont Netherlands	5	36 0.5×	47 1.3×	15 0.6×	72 4.8×	9 0.6×	16	117
Evgueniy Hadjiev Bulgaria	6	43 0.6×	25 0.7×	7 0.3×	23 1.5×	4 0.3×	12	142
Sergiy Klymenko Ukraine	8	81 1.1×	24 0.6×	25 1.0×	29 1.9×	2 0.1×	25	134
Paul Fordjour United States	3	115 1.6×	14 0.4×	44 1.8×	19 1.3×	3 0.2×	3	140
Dong‐Anh Khuong‐Quang Australia	5	40 0.6×	72 1.9×	23 0.9×	16 1.1×	46 3.3×	12	118

Countries citing papers authored by Heba Ijaz

Since Specialization

Citations

This map shows the geographic impact of Heba Ijaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heba Ijaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heba Ijaz more than expected).

Fields of papers citing papers by Heba Ijaz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heba Ijaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heba Ijaz. The network helps show where Heba Ijaz may publish in the future.

Co-authorship network of co-authors of Heba Ijaz

This figure shows the co-authorship network connecting the top 25 collaborators of Heba Ijaz. A scholar is included among the top collaborators of Heba Ijaz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heba Ijaz. Heba Ijaz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

4 of 4 papers shown

1.

Cole, Kristina A., Heba Ijaz, Lea F. Surrey, et al.. (2023). Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma. Cancer. 129(14). 2245–2255. 16 indexed citations

2.

Cole, Kristina A., Heba Ijaz, Lea F. Surrey, et al.. (2021). Abstract CT029: Pediatric phase 2 trial of the WEE1 inhibitor adavosertib (AZD1775) and irinotecan: A Children's Oncology Group Study (ADVL1312). Cancer Research. 81(13_Supplement). CT029–CT029. 1 indexed citations

3.

Cole, Kristina A., Sharmistha Pal, Rachel A. Kudgus, et al.. (2019). Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312). Clinical Cancer Research. 26(6). 1213–1219. 48 indexed citations

4.

Dai, Yan, et al.. (2017). SIRT1 activates the expression of fetal hemoglobin genes. American Journal of Hematology. 92(11). 1177–1186. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact